Last update 20 Mar 2025

IMA-203

Overview

Basic Info

Drug Type
TCR-T Cell therapy
Synonyms
+ [2]
Target
Action
inhibitors
Mechanism
PRAME inhibitors(PRAME nuclear receptor transcriptional regulator inhibitors), Immunologic cytotoxicity, T lymphocyte replacements
Inactive Indication
Originator Organization
Active Organization
Drug Highest PhasePhase 3
First Approval Date-
RegulationRegenerative Medicine Advanced Therapy (United States)
Login to view timeline

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Acral Lentiginous Malignant MelanomaPhase 3
United States
14 Jan 2025
Melanoma, Cutaneous MalignantPhase 3
United States
14 Jan 2025
Hematologic NeoplasmsPhase 2
United States
11 Jul 2020
Solid tumorPhase 2
United States
04 Apr 2019
Relapsed Solid NeoplasmPhase 1
United States
14 May 2019
Relapsed Solid NeoplasmPhase 1
Germany
14 May 2019
Uveal MelanomaPhase 1
Germany
-
Endometrial CarcinomaPreclinical
United States
27 Oct 2023
Ovarian CancerPreclinical
United States
27 Oct 2023
Synovial SarcomaPreclinical
United States
27 Oct 2023
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 1
38
ACTengine IMA203 TCR-T
(1–10x10^9 total TCR-T cells)
(daeptekrnw) = eeawftzzqo veybnqmwta (ccbveuwuzm )
Positive
05 Nov 2024
ACTengine IMA203 TCR-T
(melanoma + 1–10x10^9 total TCR-T cells)
(kzhcolqvff) = nexybdvveq sueoapqurw (mxqfzbvbde )
Phase 3
28
(All melanoma)
(lwxcxsovdy) = uxfqptitvp mudhfoxthc (tjybsjfdxm )
Positive
10 Oct 2024
(Cutaneous melanoma patients)
(lwxcxsovdy) = ygvzgvbhqy mudhfoxthc (tjybsjfdxm )
Phase 1
45
(Phase 1a + Cohort A)
(fyvqbmkyqq) = ztlgvlnoga zwnnudkeyv (mtoubfmwhr )
Positive
08 Nov 2023
(Phase 1a)
(okadvjgmee) = acxsaautzo gtbzedgobz (hnfgkxcflz )
Phase 1
11
(gtklgotndc) = xdgverztim ltqofktdda (yljjtsngpa )
Positive
26 Oct 2023
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free